Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2a study of Allocetra-OTS alone or with PD-1 blockade in advanced solid tumors
MOH_2022-08-17_011988Phase 2Completed
- Sponsor
- Enlivex Therapeutics RDO
- Start
- Aug 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of Allocetra in Non-hematologic malignancy (3 arms), sponsored by Enlivex Therapeutics RDO. Started Aug 2022; status: completed.
02
Drugs
Allocetra
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on MOH_2022-08-17_011988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-17_011988.